Perspectives of vaccination with 13!valent pneumococcal vaccine in adults with chronic respiratory diseases

Aim. The aim of this study was to investigate safety and clinical efficacy of 13valent conjugated pneumococcal vaccine (PCV13) and 23valent poly saccharide pneumococcal vaccine (PPV23) in patients with chronic obstructive pulmonary disease (COPD) and asthma and to assess impact of vac
cination on quality on life. 

Methods. This was a prospective comparative study. Clinical efficacy and safety were evaluated using data on systemic and local adverse reactions during a month after vaccination, changes in lung function and quality of life (QoL in 6 months after vaccination. Lung function was assessed before and 1 and 6 months after vaccination. QoL was measured before and 6 months after vaccination using CAT test in COPD patients and ACQ ques tionnaire in asthma patients. 

Results. The study involved 58 patients with COPD and 59 patients with asthma. Of them, 33 and 34 patients, respectively, were vaccinated with PCV13 and 25 patients of each group were vaccinated with PPV23. A rate of systemic and local adverse reactions did not differ significantly between patients vaccinated with PCV13 or PPV23. Patients with both COPD and asthma vaccinated with PCV13 demonstrated more significant increase in FEV1. QoL improved in all vaccinated patients. Worsening of the disease was not noted in any patient.

Conclusion. In patients with COPD and asthma, lung function tended to improvement and QoL significantly improved in 6 months after vaccina tion with PCV13 or PPV23. Both vaccines were well tolerated.

1. WHO Weekly Epidemiological Record, 23 March 2007. 2007; 12 (82): 93–104. www.who.int/wer

2. Лукачев И.В. Специфический IgG, IgEответ и течение бронхиальной астмы у детей в процессе вакцинации препаратами "Пневмо23" и "АктХиб": Дисс. …канд. мед. наук. М.; 2004. / Lukachev I.V. Specific IgG dependent and IgEdependent responses and a course of childhood bronchial asthma under vaccination with "Pneumo23" and "AktKhib" vaccines: Dis. Moscow; 2004 (in Russian).

3. Инструкция по применению лекарственного препарата для медицинского применения Превенар 13 от 12.07.12. ЛП 000798120712. / Prevenar 13. Drug label of 12.07.2012 LP 000798120712 (in Russian).

4. Инструкция по применению лекарственного препарата для медицинского применения Синфлорикс. ЛП 001412110112. / Synflorix. Drug label LP 001412110112 (in Russian).

5. Лобзин Ю.В., Сидоренко С.В., Харит С.М. и др. Серотипы Streptococcus pneumoniae, вызывающих ведущие но зологические формы пневмококковых инфекций. Журнал инфектологии. 2013; 5 (4): 35–41. / Lobzin Yu.V., Sidorenko S.V., Kharit S.M., et al. Streptococcus pneumoni ae strains causing the most common pneumococcal infections. Zhurnal infektologii. 2013; 5 (4): 35–41 (in Russian).

6. Barton M., Wasfy S., Dipchand A.I. et al. Seven – valent pneumococcal conjugate vaccine in pediatric solid organtransplant recipients: a prospective study of safety and immunogenicity. Pediatr. Infect. Dis. 2009; 28 (8):688–692.

7. Chisholm J.C. Reimmunization after therapy for children cancer. Clin. Infect. Dis. 2007; 44 (5): 643–645.

8. PCV 13 EPAR: CHMP variation assessment report, Dec 2011, available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR – Assessment_Report_'Variation/human/001104/WC500119784.pdf

9. Paradiso P. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin. Infect. Dis. 2012; 55 (2): 259–264.

10. Игнатова Г.Л., Родионова О.В. Клиническая эффективность вакцинации конъюгированной пневмококковой вакциной пациентов с хронической бронхолегочной патологией в Городском пульмонологическом центре Челябинска. Пульмонология. 2013; 6: 38–42. / Ignato'va G.L., Rodionova O.V. Clinical efficacy of vaccination against pneumococcal infection of patients with chronic respiratory disease in Chelyabinsk city pulmonology center. Pul'monologiya. 2013; 6: 38–42 (in Russian).

11. http://www.CATestonline.org

12. Juniper E.F., O'Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma con trol. Eur. Respir. J. 1999; 14: 902–907.

13. World Health Organization. Global surveillance, prevention, and control of chronic respiratory diseases: a compre hensive approach. http://www.who.int/gard/publications/GARD%20Book%202007.pdf. Accessed September 3, 2012.[WHO GARD book].

14. Allegra L., Konietzko N., Leophonte P. et al. Comparative safety and efficacy of sparfloxacinin the treatment of acute exacerbations of chronic obstructive pulmonary disease: a doubleblind,randomized, parallel, multicenter study. J. Antimicrob. Chemother. 1996; 37 (Suppl. A): 93–104.

15. Garcha D.S., Thurston S.J., Patel A.R. et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012; 67(12): 1075–1080.

16. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of COPD. 2014.

17. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of COPD; 2011. http://www.goldcopd.org/.Accessed Sept. 10, 2012. [GOLD Report]

18. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Инфекционное обострение ХОБЛ: Практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей: М.; 2005: 37. / Chuchalin A.G.,Sinopal'nikov A.I., Kozlov R.S. et al. Infection Exacerbation of COPD: Practical Guidelines on Diagnosis, Treatment and Prevention. Practical handbook. [Infektsionnoe obostrenie KhOBL: prakticheskie rekomendatsii po diagnos tike, lecheniyu i profilaktike: Posobie dlya vrachey]. Moscow; 2005: 37 (in Russian).

19. Протасов А.Д. Иммунологический и клинический эффекты сочетанного применения вакцин против пневмококковой, гемофильной типа b инфекций и гриппа у больных с хронической обструктивной болезнью легких: Дисс. … канд. мед. наук. М.; 2012. / Protasov A.D. Immune and clinical responses on simultaneous vaccination against pneumococcus, btype Haemophilus influenza and influenza infections in patients with chronic obstructive pulmonary disease: Dis. Moscow; 2012 (in Russian).

20. Протасов А.Д., Жестков А.В., Костинов М.П. Динамика показателей функциональных тестов у пациентов с хронической обструктивной болезнью легких через три месяца после комплексной вакцинации против пневмококка, гемофильной инфекции типа B и гриппа. Вестник современной клинической медицины. 2010; 3 (3): 35–39. / Protasov A.D., Zhestkov A.V., Kosti'nov M.P. Functional dynamics in patients with chronic obstructive pulmonary disease 3 months after vaccination against pneumococcus, Haemophilus influenzae type B and influenza. Vestnik sovremennoy klinicheskoy meditsiny. 2010; 3 (3): 35–39 (in Russian).

21. Костинов М.П., ред. От профилактического к терапевтическому эффекту вакцин против пневмококковой и гемофильной типа B инфекций у пациентов с бронхолегочной патологией. М.; 2007. / Kostinov M.P., ed. From Preventive to Therapeutic Effect of Vaccination Against Pneumococcal and Haemophilus Influenzae Type B Infections in Patients with Respiratory Diseases. [Ot profilakticheskogo k terapevticheskomu effektu vaktsin protiv pnevmokokkovoy i gemofil'noy tipa b infektsiy u patsientov s bronkholegochnoy patologiey]. Moscow; 2007 (in Russian).

22. Костинов М.П. Первый опыт применения конъюгированной 13валентной пневмококковой вакцины у больных. В кн.: Сборник материалов VIII Национального конгресса терапевтов. М.; 2013. 147. / Kostinov M.P. The first clinical experience of vaccination with conjugated 13-valent pneumococcal vaccine. In: The VIII National Congress of Therapeutists Proceedings. [Sbornik materialov VIII Natsional'nogo kongressa terapevtov]. Moscow; 2013: 147 (in Russian).

23. Протасов А.Д., Жестков А.В., Костинов М.П. Качество жизни больных с бронхолегочной патологией, вакцинированных против респираторных инфекций. В кн.: Сборник материалов VIII Национального конгресса терапевтов. М.; 2013. 242. / Protasov A.D., Zhestkov A.V.,Kostinov M.P. Quality of life in patients with respiratory disease vaccinated against respiratory infections. In: The VIII National Congress of Therapeutists Proceedings. [Sbornik trudov VIII Natsional'nogo kongressa terapevtov]. Moscow; 2013: 242 (in Russian).

24. Протасов А.Д., Жестков А.В., Костинов М.П. Сравнительная оценка безопасности применения конъюгированной и полисахаридной пневмококковых вакцин у больных с хронической обструктивной болезнью легких. В кн.: Сборник тезисов XXIII Национального конгресса по болезням органов дыхания. Казань; 2013. 75–76. / Protasov A.D., Zhestkov A.V., Kostinov M.P. Comparison of safety of conjugated and polysaccharide pneumococcal vaccines in patients with chronic obstructive pulmonary disease. In: XXIII National Congress on Res piratory Diseases Proceedings. [Sbornik tezisov XXIII Natsional'nogo kongressa po boleznyam organov dykhaniya]. Kazan'; 2013: 75–76 (in Russian).